Other than ibrutinib, clients with M-CLL, devoid of TP53 aberrations and in good shape adequate to tolerate FCR therapy, should be good candidates with the latter, with the benefit being that this procedure might be finished in 6 months whilst ibrutinib should be taken indefinitely. This option could well be specially precious for non-compliant suf